Literature DB >> 12532335

Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer.

Eddy S Leman1, Michael C Madigan, Gisela Brünagel, Natsuki Takaha, Donald S Coffey, Robert H Getzenberg.   

Abstract

Nuclear shape and the underlying nuclear structure, the nuclear matrix in cancer cells. Since the NM composition is considered to maintain nuclear shape and architecture, nuclear matrix proteins (NMPs) may be involved in transformation. Our laboratory has recently characterized a subset of NMPs that are associated with prostate cancer development in the transgenic adenocarcinoma of mouse prostate (TRAMP) model. One of the identified NMPs, E3E, has a similar molecular weight (22 kDa) with a protein known as HMGI(Y). HMGI(Y) belongs to a group of non-histone and chromatin-associated proteins, high-mobility-group (HMG) proteins, and it has been shown to associate with the NM. HMGI(Y) has been reported to be elevated in different types of cancer including prostate cancer. In this study, we examined the expression of HMGI(Y) protein in the NMP composition of the TRAMP model during the progression from normal to neoplasia. The expression of HMGI(Y) in the NMP extracts of three prostatic epithelial cell lines derived from a 32-week TRAMP mouse: TRAMP-C1, TRAMP-C2, and TRAMP-C3 was also examined. Using both one-dimensional and high-resolution two-dimensional immunoblot analyses, we found that: (i) HMGI(Y) is a nuclear matrix protein expressed as two protein bands with MW of 22-24 kDa and (ii) HMGI(Y) expression is correlated with neoplastic and malignant properties in late stage TRAMP prostate tumors. Overall, these findings support the evidence that HMGI(Y) can be utilized as a marker and prognostic tool for prostate cancer. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12532335     DOI: 10.1002/jcb.10368

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  9 in total

1.  Comparison of nuclear matrix proteins between gastric cancer and normal gastric tissue.

Authors:  Qin-Xian Zhang; Yi Ding; Zhuo Li; Xiao-Ping Le; Wei Zhang; Ling Sun; Hui-Rong Shi
Journal:  World J Gastroenterol       Date:  2004-06-15       Impact factor: 5.742

2.  c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus.

Authors:  Sherif F Louis; Bart J Vermolen; Yuval Garini; Ian T Young; Amanda Guffei; Zelda Lichtensztejn; Fabien Kuttler; Tony C Y Chuang; Sharareh Moshir; Virginie Mougey; Alice Y C Chuang; Paul Donald Kerr; Thierry Fest; Petra Boukamp; Sabine Mai
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-27       Impact factor: 11.205

Review 3.  High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma.

Authors:  S S Liau; E Whang
Journal:  Surgeon       Date:  2009-10       Impact factor: 2.392

4.  Diagnostic significance of serum HMGB1 in colorectal carcinomas.

Authors:  Hanna Lee; Meiying Song; Nara Shin; Chang Hoon Shin; Byung Soh Min; Hyon-Suk Kim; Jong Shin Yoo; Hoguen Kim
Journal:  PLoS One       Date:  2012-04-04       Impact factor: 3.240

Review 5.  Epigenetics of prostate cancer: beyond DNA methylation.

Authors:  W A Schulz; J Hatina
Journal:  J Cell Mol Med       Date:  2006 Jan-Mar       Impact factor: 5.310

Review 6.  Clinical Value of High Mobility Group Box 1 and the Receptor for Advanced Glycation End-products in Head and Neck Cancer: A Systematic Review.

Authors:  Austin Nguyen; Sheila Bhavsar; Erinn Riley; Gabriel Caponetti; Devendra Agrawal
Journal:  Int Arch Otorhinolaryngol       Date:  2016-04-19

7.  High mobility group box 1 promotes the epithelial-to-mesenchymal transition in prostate cancer PC3 cells via the RAGE/NF-κB signaling pathway.

Authors:  Jingliang Zhang; Shuai Shao; Donghui Han; Yuerong Xu; Dian Jiao; Jieheng Wu; Fa Yang; Yufeng Ge; Shengjia Shi; Yu Li; Weihong Wen; Weijun Qin
Journal:  Int J Oncol       Date:  2018-05-23       Impact factor: 5.650

Review 8.  HMGA1 in cancer: Cancer classification by location.

Authors:  Yuhong Wang; Lin Hu; Yushuang Zheng; Lingchuan Guo
Journal:  J Cell Mol Med       Date:  2019-01-07       Impact factor: 5.310

Review 9.  HMGB1: endogenous danger signaling.

Authors:  John R Klune; Rajeev Dhupar; Jon Cardinal; Timothy R Billiar; Allan Tsung
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.